Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label neoadjuvant study of iniparib (SAR240550/BSI-201) plus weekly paclitaxel versus weekly paclitaxel alone in triple-negative breast cancer
2010-018960-17Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iniparib and paclitaxel in triple-negative breast cancer (TNBC) (3 arms), sponsored by Sanofi. Primary endpoints: Pathologic complete response in the breast and Pathologic complete response in the breast and axilla. Started Apr 2010; status: completed.
02
Drugs
iniparibpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2010-018960-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018960-17.